RGD DISEASE ONTOLOGY - ANNOTATIONS
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
Term: Drug-Induced Dyskinesia
Accession: DOID:9008394
browse the term
Definition: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
Synonyms: exact_synonym: Drug-Induced Dyskinesias; Medication Induced Dyskinesia; Medication-Induced Dyskinesias
primary_id: MESH:D004409
xref: EFO:1000904
G
ABAT
4-aminobutyrate aminotransferase
ISO
RGD
PMID:6445277 PMID:7740056
RGD:10047091 RGD:1598524
NCBI chr 6:33,385,779...33,471,348
Ensembl chr 6:33,376,996...33,471,326
G
CACNA1D
calcium voltage-gated channel subunit alpha1 D
ISO
RGD
PMID:18947822
RGD:6906919
NCBI chr20:36,189,986...36,488,460
Ensembl chr20:36,191,810...36,613,686
G
CAT
catalase
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:19109989
NCBI chr18:33,383,005...33,422,447
Ensembl chr18:33,383,005...33,422,447
G
CCK
cholecystokinin
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:2320253
NCBI chr23:11,414,254...11,419,990
Ensembl chr23:11,414,249...11,454,198
G
COMT
catechol-O-methyltransferase
ISO
RGD
PMID:16437585
RGD:2289781
NCBI chr26:29,359,930...29,381,854
Ensembl chr26:29,360,356...29,366,008
G
CYP2D15
cytochrome P450 family 2 subfamily D member 15
ISO
RGD
PMID:12629505
RGD:1358549
NCBI chr10:23,255,259...23,259,380
Ensembl chr10:23,255,249...23,259,298
G
DBN1
drebrin 1
ISO
levodopainduced; protein:increased expression:striatum:
RGD
PMID:23241013
RGD:10398811
NCBI chr 4:35,899,969...35,913,015
Ensembl chr 4:35,889,392...35,912,507
G
DDC
dopa decarboxylase
ISO
associated with Parkinson Disease; protein:decreased expression:striatum (rat)
RGD
PMID:20232137
RGD:5128860
NCBI chr18:1,802,239...1,876,714
Ensembl chr18:1,803,273...1,867,616
G
DRD1
dopamine receptor D1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:7845605 PMID:10858612 PMID:16982285 PMID:19520364
NCBI chr 4:37,550,454...37,554,641
Ensembl chr 4:37,549,708...37,553,287
G
DRD2
dopamine receptor D2
ISO
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:7845605 PMID:10534246 PMID:14629710 PMID:18707801
RGD:2311579
NCBI chr 5:19,732,842...19,795,241
Ensembl chr 5:19,732,836...19,795,241
G
DRD3
dopamine receptor D3
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:20945430
NCBI chr33:18,369,362...18,414,465
Ensembl chr33:18,372,865...18,412,277
G
EGR1
early growth response 1
ISO
RGD
PMID:22153973
RGD:10395307
NCBI chr11:26,046,195...26,049,806
Ensembl chr11:26,046,228...26,048,575
G
FOSB
FosB proto-oncogene, AP-1 transcription factor subunit
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:17219962
NCBI chr 1:110,088,686...110,092,818
Ensembl chr 1:110,087,036...110,092,818
G
GAD1
glutamate decarboxylase 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:9767399
NCBI chr36:15,351,289...15,391,701
Ensembl chr36:15,349,683...15,391,824
G
GCH1
GTP cyclohydrolase 1
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:15659429
NCBI chr 8:30,733,422...30,784,067
Ensembl chr 8:30,732,608...30,784,156
G
GDNF
glial cell derived neurotrophic factor
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:11168568
NCBI chr 4:70,966,694...70,991,860
Ensembl chr 4:70,971,432...70,989,714
G
GLUL
glutamate-ammonia ligase
ISO
RGD
PMID:6445277
RGD:10047091
NCBI chr 7:15,730,898...15,740,241
Ensembl chr 7:15,730,898...15,740,241
G
GRK6
G protein-coupled receptor kinase 6
ISO
associated with Parkinson Disease
RGD
PMID:20410529
RGD:5684919
NCBI chr 4:35,927,470...35,943,218
Ensembl chr 4:35,913,472...35,943,221
G
GSK3B
glycogen synthase kinase 3 beta
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:26997328
RGD:13792768
NCBI chr33:23,458,369...23,659,878
Ensembl chr33:23,463,767...23,659,666
G
HOMER1
homer scaffold protein 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:24126708
NCBI chr 3:27,395,337...27,525,822
Ensembl chr 3:27,400,839...27,523,320
G
HTR1A
5-hydroxytryptamine receptor 1A
ISO
RGD
PMID:21352823
RGD:5683628
NCBI chr 2:50,005,277...50,006,548
Ensembl chr 2:50,002,740...50,006,548
G
MAPT
microtubule associated protein tau
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:25511986
RGD:13800920
NCBI chr 9:9,572,174...9,674,082
Ensembl chr 9:9,570,557...9,674,349
G
MTOR
mechanistic target of rapamycin kinase
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:23938307
RGD:10040953
NCBI chr 2:84,818,893...84,939,283
Ensembl chr 2:84,787,708...84,939,114
G
PDYN
prodynorphin
treatment severity
ISO
CTD Direct Evidence: marker/mechanism associated with Parkinsonism associated with Parkinsonism;protein:increased expression:striatum
CTD RGD
PMID:9767399 PMID:10869049 PMID:17884291 PMID:21737418
RGD:401850563 RGD:401851046 RGD:401900134
NCBI chr24:19,043,955...19,057,413
Ensembl chr24:19,053,870...19,056,364
G
PENK
proenkephalin
treatment disease_progression
ISO
mRNA:increased expression:brain:striatum: associated with Parkinsonism associated with Parkinsonism;mRNA:increased expression:striatum CTD Direct Evidence: marker/mechanism
RGD CTD
PMID:9767399 PMID:10869049 PMID:20456008 PMID:26113400
RGD:10003039 RGD:401851054 RGD:401900134
NCBI chr29:7,757,543...7,763,137
Ensembl chr29:7,757,857...7,762,398
G
PPP1R1B
protein phosphatase 1 regulatory inhibitor subunit 1B
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:27771532
RGD:13514053
NCBI chr 9:22,838,198...22,847,924
Ensembl chr 9:22,838,576...22,848,142
G
RASGRF1
Ras protein specific guanine nucleotide releasing factor 1
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:21115823
NCBI chr 3:57,995,092...58,085,395
Ensembl chr 3:57,995,786...58,085,380
G
RELA
RELA proto-oncogene, NF-kB subunit
ISO
protein:increased expression:nucleus, brain
RGD
PMID:18590723
RGD:2298778
NCBI chr18:51,550,003...51,558,861
Ensembl chr18:51,550,040...51,558,875
G
RGS4
regulator of G protein signaling 4
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:24969021
RGD:13524515
NCBI chr38:19,771,454...19,778,917
Ensembl chr38:19,771,441...19,779,190
G
RGS9
regulator of G protein signaling 9
ISO
CTD Direct Evidence: marker/mechanism|therapeutic
CTD
PMID:18160641 PMID:24663062
NCBI chr 9:14,809,977...14,905,299
Ensembl chr 9:14,809,864...14,905,197
G
TH
tyrosine hydroxylase
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:15659429
NCBI chr18:46,327,136...46,334,973
Ensembl chr18:46,327,137...46,335,602
G
CYP1A2
cytochrome P450 family 1 subfamily A member 2
treatment
ISO
associated with schizophrenia
RGD
PMID:10889552
RGD:1358545
NCBI chr30:37,818,400...37,824,192
Ensembl chr30:37,799,140...37,824,135
G
DRD3
dopamine receptor D3
ISO
associated with schizophrenia
RGD
PMID:12960753
RGD:1581250
NCBI chr33:18,369,362...18,414,465
Ensembl chr33:18,372,865...18,412,277
G
SOD2
superoxide dismutase 2
ISO
associated with schizophrenia
RGD
PMID:12960753
RGD:1581250
NCBI chr 1:48,943,472...48,955,158
Ensembl chr 1:48,836,262...48,955,706
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all